3.9 Article

EUROASPIRE III. Management of cardiovascular risk factors in asymptomatic high-risk patients in general practice: cross-sectional survey in 12 European countries

出版社

SAGE PUBLICATIONS LTD
DOI: 10.1097/HJR.0b013e3283383f30

关键词

EUROASPIRE; guidelines; primary prevention

资金

  1. AstraZeneca
  2. Bristol-Myers Squibb
  3. GlaxoSmithKline
  4. Pfizer
  5. Sanofi-Aventis
  6. Servier and Merck/Schering-Plough
  7. Novartis
  8. European Society of Cardiology

向作者/读者索取更多资源

Objective To determine whether the 2003 Joint European Societies' guidelines on cardiovascular disease prevention in people at high cardiovascular risk have been followed in general practice. Design Cross-sectional survey. Methods The EUROASPIRE survey was carried out in 2006-2007 in 66 general practices in 12 European countries. Patients without a history of coronary or other atherosclerotic disease either started on antihypertensive and/or lipid-lowering and/or antidiabetes treatments were identified retrospectively, interviewed and examined at least 6 months after the start of medication. Results Four thousand, three hundred and sixty-six high-risk individuals (57.7% females) were interviewed (participation rate 76.7%). Overall, 16.9% smoked cigarettes, 43.5% had body mass index >= 30 kg/m(2), 70.8% had blood pressure >= 140/90mmHg (>= 130/80 in people with diabetes mellitus), 66.4% had total cholesterol >= 5.0mmol/l (>= 4.5mmol/l in people with diabetes) and 30.2% reported a history of diabetes. The risk factor control was very poor, with only 26.3% of patients using antihypertensive medication achieving the blood pressure goal, 30.6% of patients on lipid-lowering medication achieving the total cholesterol goal and 39.9% of patients with self-reported diabetes having haemoglobin A1c <= 6.1%. The use of blood pressure-lowering medication in people with hypertension was: beta-blockers 34.1%, angiotensin-converting enzyme inhibitors/angiotensin II receptor blockers 60.8%, calcium channel blockers 26.3%, diuretics 36.9%. Statins were prescribed in 47.0% of people with hypercholesterolemia. About 22.0% of all patients were on aspirin or other antiplatelet medication. Conclusion The EUROASPIRE III survey in general practice shows that the lifestyle of people being treated as high cardiovascular risk is a major cause of concern with persistent smoking and high prevalence of both obesity and central obesity. Blood pressure, lipid and glucose control are completely inadequate with most patients not achieving the targets defined in the prevention guidelines. Primary prevention needs a systematic, comprehensive, multidisciplinary approach, which addresses lifestyle and risk factor management by general practitioners, nurses and other allied health professionals, and a health care system which invests in prevention. Eur J Cardiovasc Prev Rehabil 17:530-540 (C) 2010 The European Society of Cardiology

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

3.9
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据